Evidence map›Paper›PMID 33262073›Full record

ArticleCytotherapy2021

Human umbilical cord mesenchymal stromal cells as an adjunct therapy with therapeutic hypothermia in a piglet model of perinatal asphyxia.

Nicola J Robertson, Christopher Meehan, Kathryn A Martinello, Adnan Avdic-Belltheus, Tiziana Boggini, Tatenda Mutshiya, Ingran Lingam, Qin Yang, Magdalena Sokolska, Xenia Charalambous and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cytotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Nicola J RobertsonInstitute for Women's Health, University College London, London, UK. Electronic address: n.robertson@ucl.ac.uk.
Christopher MeehanInstitute for Women's Health, University College London, London, UK.
Kathryn A MartinelloInstitute for Women's Health, University College London, London, UK.
Adnan Avdic-BelltheusInstitute for Women's Health, University College London, London, UK.
Tiziana BogginiInstitute for Women's Health, University College London, London, UK.
Tatenda MutshiyaInstitute for Women's Health, University College London, London, UK.
Ingran LingamInstitute for Women's Health, University College London, London, UK.
Qin YangInstitute for Women's Health, University College London, London, UK.
Magdalena SokolskaUniversity College London Hospitals NHS Foundation Trust, London, UK.
Xenia CharalambousInstitute for Women's Health, University College London, London, UK.
Alan BainbridgeUniversity College London Hospitals NHS Foundation Trust, London, UK.
Mariya HristovaInstitute for Women's Health, University College London, London, UK.
Boris W KramerDepartment of Pediatrics, University of Maastricht, Maastricht, the Netherlands.
Xavier GolayInstitute for Women's Health, University College London, London, UK.
Ben WeilRoyal Free London NHS Foundation Trust, London, UK.
Mark W LowdellInstitute for Women's Health, University College London, London, UK; Royal Free London NHS Foundation Trust, London, UK.

Funding

Department of HealthMedical Research Council MR/M006743/1
6 · The paper itself

Abstract

backgroundWith therapeutic hypothermia (HT) for neonatal encephalopathy, disability rates are reduced, but not all babies benefit. Pre-clinical rodent studies suggest mesenchymal stromal cells (MSCs) augment HT protection.

aimsThe authors studied the efficacy of intravenous (IV) or intranasal (IN) human umbilical cord-derived MSCs (huMSCs) as adjunct therapy to HT in a piglet model.

methodsA total of 17 newborn piglets underwent transient cerebral hypoxia-ischemia (HI) and were then randomized to (i) HT at 33.5°C 1-13 h after HI (n = 7), (ii) HT+IV huMSCs (30 × 10

resultsHI severity was similar between groups. Amplitude-integrated electroencephalogram (aEEG) recovery was more rapid for HT+IN huMSCs compared with HT from 25 h to 42 h and 49 h to 54 h (P ≤ 0.05). MRS phosphocreatine/inorganic phosphate was higher on day 2 in HT+IN huMSCs than HT (P = 0.035). Comparing HT+IN huMSCs with HT and HT+IV huMSCs, there were increased OLIG2 counts in hippocampus (P = 0.011 and 0.018, respectively), internal capsule (P = 0.013 and 0.037, respectively) and periventricular white matter (P = 0.15 for IN versus IV huMSCs). Reduced TUNEL-positive cells were seen in internal capsule with HT+IN huMSCs versus HT (P = 0.05). PKH-labeled huMSCs were detected in the brain 12 h after IN administration.

conclusionsAfter global HI, compared with HT alone, the authors saw beneficial effects of HT+IN huMSCs administered at 24 h and 48 h (30 × 10

Indexed as

Hypothermia, InducedMesenchymal Stem CellsAnimalsAnimals, NewbornAsphyxiaDisease Models, AnimalHumansSwineUmbilical Cord

Identifiers

PMID33262073
PMCPMC8139415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.